Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,463
  • Shares Outstanding, K 29,383
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,810 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.06
Trade EQ with:

Options Overview

Details
  • Implied Volatility 103.05%
  • Historical Volatility 108.27%
  • IV Percentile 72%
  • IV Rank 65.26%
  • IV High 143.28% on 08/09/21
  • IV Low 27.46% on 07/20/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 91
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 168
  • Open Int (30-Day) 75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.36
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -9.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.79 +33.19%
on 08/20/21
6.95 -8.20%
on 08/26/21
+1.18 (+22.69%)
since 08/17/21
3-Month
4.79 +33.19%
on 08/20/21
6.95 -8.20%
on 08/26/21
+0.43 (+7.23%)
since 06/17/21
52-Week
3.47 +83.86%
on 11/10/20
11.33 -43.69%
on 02/12/21
+0.01 (+0.16%)
since 09/17/20

Most Recent Stories

More News
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will...

EQ : 6.38 (+7.59%)
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

--The Type B lupus nephritis cohort has been expanded to include newly diagnosed patients, in addition to refractory patients, and will evaluate a single subcutaneous dose level based on Type A PK/PD results...

EQ : 6.38 (+7.59%)
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update

--Announced plans to initiate a Phase 3 pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease

EQ : 6.38 (+7.59%)
Equillium to Present at the BTIG Virtual Biotechnology Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual...

EQ : 6.38 (+7.59%)
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Single pivotal Phase 3 study in acute graft-versus-host disease to

EQ : 6.38 (+7.59%)
Stocks in play: EQ Inc.

Has completed the acquisition of all of the shares of Integrated Rewards Inc., and its consumer facing ...

EQ : 6.38 (+7.59%)
EQ Works Data Revenue Increases 12% Year-over-Year and Forecasts 60% Revenue Growth Next Quarter as Retail Reopens

eResearch Corp. (www.eresearch.com) published a 14-page update Equity Research Report on EQ Inc. (TSXV:EQ; ...

ADBE : 654.48 (-1.60%)
INUV : 0.7149 (+4.33%)
EQ : 6.38 (+7.59%)
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Itolizumab continues to demonstrate favorable safety and efficacy profile

EQ : 6.38 (+7.59%)
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a poster presented yesterday at the CYTO...

EQ : 6.38 (+7.59%)
Equillium to Present at the JMP Securities Life Sciences Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities...

EQ : 6.38 (+7.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 7.18
2nd Resistance Point 6.79
1st Resistance Point 6.59
Last Price 6.38
1st Support Level 6.00
2nd Support Level 5.61
3rd Support Level 5.41

See More

52-Week High 11.33
Fibonacci 61.8% 8.33
Fibonacci 50% 7.40
Fibonacci 38.2% 6.47
Last Price 6.38
52-Week Low 3.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar